This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Letters to the Editor

What Do We Know About Insulin Resistance and Glucose Metabolism in Patients With Schizophrenia Treated With Antipsychotics?

Jamie Karagianis, MD, FRCPC; Vicki Poole Hoffmann, PharmD; Virginia L. Stauffer, PharmD; Tamás Treuer, MD, PhD; Belen Arranz, MD, PhD; and Luis San, MD, PhD

Published: May 15, 2007

Article Abstract

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

Sir: In their recent article on glucose metabolism in schizophrenic patients during treatment with olanzapine or quetiapine, Henderson et al.1 have raised some important issues.

We wish to begin by complimenting the authors on their efforts to clarify a complex issue that attracts much attention in the literature. Their article is important for hypothesis generation in the area of understanding insulin resistance issues among patients treated with antipsychotics.’ ‹


Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 68

Quick Links: Psychotic Disorders , Schizophrenia and Schizoaffective Disorders

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Insights

LAI Antipsychotics in Schizophrenia: Long-term Outcomes of Early Use

Using data from the...

Read More...